These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28863346)

  • 1. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
    Tu YS; He J; Liu H; Lee HC; Wang H; Ishizawa J; Allen JE; Andreeff M; Orlowski RZ; Davis RE; Yang J
    Neoplasia; 2017 Oct; 19(10):772-780. PubMed ID: 28863346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
    Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
    PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
    Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
    Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
    Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
    Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
    Chen S; Zhang Y; Zhou L; Leng Y; Lin H; Kmieciak M; Pei XY; Jones R; Orlowski RZ; Dai Y; Grant S
    Blood; 2014 Oct; 124(17):2687-97. PubMed ID: 25208888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
    ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.